HDAC9 and X-linked myotubular myopathy: It also resulted in identification of a new therapeutic strategy for XLMTM, e.g. epigenetic modulation via HDAC inhibition, and specifically identified valproic acid as a promising drug treatment suitable for future potential translation to XLMTM patients.